FindTrial
Sign In

CRD-740

DRUG2 trials

Sponsors

Cardurion Pharmaceuticals, Inc.

Conditions

Cardiovascular DiseasesClinical PharmacologyHeart DiseasesHeart FailureHeart Failure With Preserved Ejection FractionHeart Failure With Reduced Ejection FractionPharmacokinetics

Phase 1

Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740
CompletedNCT05437094
Cardurion Pharmaceuticals, Inc.Cardiovascular Diseases, Clinical Pharmacology, Heart Failure +1
Start: 2022-06-27End: 2022-08-10Updated: 2025-05-15

Phase 2

Effectiveness of CRD-740 in Heart Failure
TerminatedNCT05409183
Cardurion Pharmaceuticals, Inc.Cardiovascular Diseases, Heart Diseases, Heart Failure +2
Start: 2022-05-26End: 2023-07-25Updated: 2024-12-19

Related Papers

Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure.
2025-10-31
Correlates of Plasma NT‐proBNP/Cyclic GMP Ratio in Heart Failure With Preserved Ejection Fraction: An Analysis of the RELAX Trial
Journal of the American Heart Association2024-03-273 citations